Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-940P is a processed pseudogene sequence derived from the U6 small nuclear RNA gene, part of the snRNA family involved in the spliceosomal excision of introns from pre-mRNA. While the parent U6 snRNA plays a vital role in RNA splicing, its pseudogenes, including RNU6-940P, are relics generated by retrotransposition events—primarily LINE-1 (L1) mediated reverse transcription—and have lost the ability to produce a functional RNA or participate in the spliceosome[4][5][1][3]. Human genomes harbor numerous U6 pseudogenes, likely reflecting historical retrotranspositional events rather than ongoing biological activity[4][5]. Some pseudogenes (not specifically RNU6-940P) can give rise to regulatory RNAs such as siRNAs, which may indirectly influence gene expression, but no evidence specifically implicates RNU6-940P in such a process[6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 940, pseudogene (RNU6-940P).